Ray T So
Overview
Explore the profile of Ray T So including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
25
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vanhove B, Marot S, So R, Gaborit B, Evanno G, Malet I, et al.
Front Immunol
. 2023 May;
14:1208705.
PMID: 37187748
[This corrects the article DOI: 10.3389/fimmu.2021.761250.].
2.
Vanhove B, Marot S, So R, Gaborit B, Evanno G, Malet I, et al.
Front Immunol
. 2021 Dec;
12:761250.
PMID: 34868003
Amino acid substitutions and deletions in the Spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can reduce the effectiveness of monoclonal antibodies (mAbs). In contrast, heterologous polyclonal...
3.
Vanhove B, Duvaux O, Rousse J, Royer P, Evanno G, Ciron C, et al.
bioRxiv
. 2021 May;
PMID: 34013271
Perfusion of convalescent plasma (CP) has demonstrated a potential to improve the pneumonia induced by SARS-CoV-2, but procurement and standardization of CP are barriers to its wide usage. Many monoclonal...
4.
Vanhove B, Duvaux O, Rousse J, Royer P, Evanno G, Ciron C, et al.
Eur J Immunol
. 2021 Feb;
51(6):1412-1422.
PMID: 33576494
Heterologous polyclonal antibodies might represent an alternative to the use of convalescent plasma or monoclonal antibodies (mAbs) in coronavirus disease (COVID-19) by targeting multiple antigen epitopes. However, heterologous antibodies trigger...